Literature DB >> 25373117

Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes.

Aimee K Santucci1, Lynn T Singer, Stephen R Wisniewski, James F Luther, Heather F Eng, John L Dills, Dorothy K Y Sit, Barbara H Hanusa, Katherine L Wisner.   

Abstract

OBJECTIVE: To examine the impact of prenatal exposure to both serotonin reuptake inhibitors (SRIs; during any trimester) and maternal major depressive disorder (MDD; by DSM-IV criteria) on infant functioning. We hypothesized that infants with prenatal exposure to SRIs or MDD would have lower psychomotor, mental, and behavioral scores compared with nonexposed infants.
METHOD: This longitudinal study included 166 mother-infant dyads: 68 with prenatal MDD/SRI (n = 41) or MDD/no SRI exposure (n = 27) and 98 nonexposed controls. Maternal depression and SRI exposure assessments were completed at or as near to 20, 30, and 36 prenatal weeks and 12, 26, 52, and 78 weeks postpartum as feasible. Infants were evaluated with the Bayley Scales of Infant Development, Second Edition, including the psychomotor (Psychomotor Development Index; PDI), cognitive (Mental Development Index; MDI), and behavioral (Behavioral Rating Scale; BRS) components. Study assessments occurred between 2003 and 2009.
RESULTS: Neither prenatal exposure to MDD/SRI nor MDD/no SRI significantly impacted overall PDI, MDI, or BRS scores. However, we observed a significant SRI exposure by time interaction for the PDI (P = .038). MDD/SRI exposure was associated with lower PDI scores at 26 (mean = 97.0) and 52 weeks (mean = 92.9) compared with nonexposed infants (mean = 101.4 and 100.5). This difference was no longer significant at the 78-week assessment.
CONCLUSIONS: Consistent with previous studies, we found no impact of prenatal MDD/SRI exposure on MDI scores. Less favorable PDI scores were observed in the first year; notably, these scores remained well within the normative range. The effects of prenatal MDD/SRI exposure on motor functioning may be transitory. A longitudinal pattern of poor developmental outcomes has not been established. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00279370. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25373117      PMCID: PMC7299636          DOI: 10.4088/JCP.13m08902

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  33 in total

1.  Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age.

Authors:  Lars Henning Pedersen; Tine Brink Henriksen; Jørn Olsen
Journal:  Pediatrics       Date:  2010-02-22       Impact factor: 7.124

2.  Early dyadic patterns of mother-infant interactions and outcomes of prematurity at 18 months.

Authors:  Margarita Forcada-Guex; Blaise Pierrehumbert; Ayala Borghini; Adrien Moessinger; Carole Muller-Nix
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

3.  Maternal depressive symptoms during pregnancy, and newborn irritability.

Authors:  B Zuckerman; H Bauchner; S Parker; H Cabral
Journal:  J Dev Behav Pediatr       Date:  1990-08       Impact factor: 2.225

4.  Neurodevelopment of children exposed in utero to antidepressant drugs.

Authors:  I Nulman; J Rovet; D E Stewart; J Wolpin; H A Gardner; J G Theis; N Kulin; G Koren
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

5.  Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children.

Authors:  Thomas G O'Connor; Jonathan Heron; Jean Golding; Michael Beveridge; Vivette Glover
Journal:  Br J Psychiatry       Date:  2002-06       Impact factor: 9.319

Review 6.  Psychoneuroendocrine processes in human pregnancy influence fetal development and health.

Authors:  Pathik D Wadhwa
Journal:  Psychoneuroendocrinology       Date:  2005-04-25       Impact factor: 4.905

7.  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.

Authors:  Katherine L Wisner; Dorothy K Y Sit; Barbara H Hanusa; Eydie L Moses-Kolko; Debra L Bogen; Diane F Hunker; James M Perel; Sonya Jones-Ivy; Lisa M Bodnar; Lynn T Singer
Journal:  Am J Psychiatry       Date:  2009-03-16       Impact factor: 18.112

Review 8.  Serotonin and brain development.

Authors:  Monsheel S K Sodhi; Elaine Sanders-Bush
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

Review 9.  The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.

Authors:  Kimberly A Yonkers; Katherine L Wisner; Donna E Stewart; Tim F Oberlander; Diana L Dell; Nada Stotland; Susan Ramin; Linda Chaudron; Charles Lockwood
Journal:  Gen Hosp Psychiatry       Date:  2009 Sep-Oct       Impact factor: 3.238

10.  SSRI'S and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media.

Authors:  A Einarson; A K Schachtschneider; R Halil; E Bollano; G Koren
Journal:  BMC Pregnancy Childbirth       Date:  2005-05-20       Impact factor: 3.007

View more
  14 in total

1.  The Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month.

Authors:  Amy L Salisbury; Kevin E O'Grady; Cynthia L Battle; Katherine L Wisner; George M Anderson; Laura R Stroud; Cynthia L Miller-Loncar; Marion E Young; Barry M Lester
Journal:  Am J Psychiatry       Date:  2015-10-30       Impact factor: 18.112

2.  One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder.

Authors:  Aimee K Santucci; Lynn T Singer; Stephen R Wisniewski; James F Luther; Heather F Eng; Dorothy K Sit; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2017 Sep/Oct       Impact factor: 4.384

Review 3.  Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles.

Authors:  Hannah K Betcher; Katherine L Wisner
Journal:  J Womens Health (Larchmt)       Date:  2019-12-03       Impact factor: 2.681

Review 4.  Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child.

Authors:  Lindsay G Lebin; Andrew M Novick
Journal:  Curr Psychiatry Rep       Date:  2022-10-01       Impact factor: 8.081

5.  Assessing the Independent and Joint Effects of Unmedicated Prenatal Depressive Symptoms and Alcohol Consumption in Pregnancy and Infant Neurodevelopmental Outcomes.

Authors:  Gretchen Bandoli; Claire D Coles; Julie A Kable; Wladimir Wertelecki; Irina V Granovska; Alla O Pashtepa; Christina D Chambers
Journal:  Alcohol Clin Exp Res       Date:  2016-04-30       Impact factor: 3.455

Review 6.  Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.

Authors:  Katharine Baratz Dalke; Amy Wenzel; Deborah R Kim
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

Review 7.  A common clinical conundrum: Antidepressant treatment of depression in pregnant women.

Authors:  Gabrielle A Mesches; Katherine L Wisner; Hannah K Betcher
Journal:  Semin Perinatol       Date:  2020-01-25       Impact factor: 3.300

8.  Fine Motor Differences and Prenatal Serotonin Reuptake Inhibitors Exposure.

Authors:  Marie-Claire A E Partridge; Amy L Salisbury; Linda L LaGasse
Journal:  J Pediatr       Date:  2016-05-20       Impact factor: 4.406

9.  Risk factors for hospitalizations associated with depression among women during the years around a birth: a retrospective cohort study.

Authors:  Jennifer Christine Fairthorne; Gillian E Hanley; Rollin Brant; Tim F Oberlander
Journal:  Int J Popul Data Sci       Date:  2019-01-21

10.  Fifty Years of Research on Prenatal Substances: Lessons Learned for the Opioid Epidemic.

Authors:  Lynn T Singer; Christina Chambers; Claire Coles; Julie Kable
Journal:  Advers Resil Sci       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.